Healthy
Conditions
Brief summary
The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled, single center study, evaluating single and multiple ascending oral doses of GLPG3067 and the combination of GLPG3067 and GLPG2222 and the combination of GLPG3067,GLPG2222 and GLPG2737 given for 14 days in healthy women of non-childbearing potential. The purpose of the study is to evaluate the safety and tolerability of single ascending oral doses and multiple ascending oral doses of GLPG3067 given to healthy women of non-childbearing potential compared to placebo, as well as of multiple oral doses of the combination of GLPG3067/GLPG2222 compared to matching placebo for each compound and multiple oral doses of the combination of GLPG3067/GLPG2222/GLPG2737 compared to matching placebo for each compound.
Interventions
GLPG3067 oral suspension, single ascending doses, daily
Placebo, oral suspension, daily
DRUGGLPG3067 multiple dose
GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
Placebo, oral suspension, daily for 14 days
DRUGGLPG3067 oral suspension
GLPG3067 oral suspension, single dose, daily
DRUGGLPG3067 oral tablet
GLPG3067 oral tablet, single dose, daily
DRUGGLPG3067/GLPG2222 multiple dose
GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
DRUGGLPG3067/GLPG2222 Placebo multiple dose
GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
DRUGGLPG3067/GLPG2222/GLPG2737 multiple dose
GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
DRUGGLPG3067/GLPG2222/GLPG2737 Placebo multiple dose
GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
Sponsors
Galapagos NV
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Female subject between 18-70 years of age, inclusive, on the date of signing the informed consent form (ICF). * Be of non-childbearing potential defined as surgically sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy), or post-menopausal (at least 12 consecutive months without menstruation, without an alternative medical cause \[including hormone replacement therapy\]). * Have a body mass index between 18-30 kg/m2, inclusive. * Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead triplicate electrocardiogram (ECG), and clinical safety laboratory tests prior to the initial study drug administration. * Discontinuation of all medications (including over-the-counter and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements, and hormonal replacement therapy for postmenopausal subjects) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) at least 2 weeks prior to the first study drug administration.
Exclusion criteria
* Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization. * Clinically significant symptoms or illness in the 3 months before screening. * Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs. * Any laboratory result considered by the investigator as clinically significant prior to study drug administration. * Creatinine clearance ≤80 mL/min using the Cockcroft-Gault formula for subjects aged ≤50 years, or creatinine clearance ≤70 mL/min using the Cockcroft-Gault formula for subjects aged \>50 years. A 24-hour urine collection to determine the actual value may be performed to confirm creatinine clearance if required. * Clinically significant abnormalities of vital signs at screening. * Clinically relevant abnormalities detected on ECG regarding either rhythm or conduction (e.g. QT interval corrected for heart rate using Fridericia's formula \[QTcF\] \>470 ms) or a known long QT syndrome. A first degree heart block or sinus arrhythmia will not be considered as a significant abnormality. * Participation in a drug, drug and device delivery system or combination, or biologic investigational research study within 8 weeks or 5 times the half-life of the investigational drug, if the half-life is known (whichever is longer) prior to initial study drug administration. Subjects who have been dosed previously with GLPG3067 in a clinical trial are allowed to participate Part 4 of this study as long as they completed their last follow-up visit or a washout period of 5 times the half-life of GLPG3067 (whichever is longer) after the last study drug administration is respected.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change versus placebo in the proportion of subjects with adverse events | Between screening and 14 days after the last dose | To assess safety and tolerability of single ascending doses, multiple ascending doses of GLPG3067 alone, or in combination with GLPG2222, or in combination with GLPG2222 and GLPG2737 versus placebo in healthy subjects |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone or in combination with GLPG2222 or in combination with GLPG2222 and GLPG2737 | Between Day 1 predose and 10 days after the last dose | To characterize pharmacokinetics of GLPG3067 after a single oral dose and of GLPG3067, GLPG2222, and GLPG2737 after multiple oral doses in healthy subjects |
| Ratio of 4-beta-hydroxycholesterol/cholesterol in plasma after multiple oral doses in healthy subjects | Day 1 predose and Day 14 | To assess the potential for CYP3A4 interaction with GLPG3067, GLPG3067 and GLPG2222, or GLPG3067 and GLPG2222 and GLPG2737 |
| Maximum observed plasma concentration of GLPG3067 (Cmax) given alone in fed state | Between Day 1 predose and 10 days after the last dose | To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state |
| Concentration in plasma observed at 24 hours post dose (C24h) of GLPG3067 given alone in fed state | Between Day 1 predose and 10 days after the last dose | To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state |
| Maximum observed plasma concentration of GLPG3067 (Cmax) given alone or in combination with GLPG2222 or in combination with GLPG2222 and GLPG2737 | Between Day 1 predose and 10 days after the last dose | To characterize pharmacokinetics of GLPG3067 after a single oral dose and of GLPG3067, GLPG2222, and GLPG2737 after multiple oral doses in healthy subjects |
| Maximum observed plasma concentration of GLPG3067 (Cmax) given alone in fasted state | Between Day 1 predose and 10 days after the last dose | To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions |
| Concentration in plasma observed at 24 hours post dose (C24h) of GLPG3067 given alone in fasted state | Between Day 1 predose and 10 days after the last dose | To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions |
| Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone in fasted state | Between Day 1 predose and 10 days after the last dose | To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions |
| Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone in fed state | Between Day 1 predose and 10 days after the last dose | To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state |
Countries
Belgium
Outcome results
None listed